June Young Chun^a, Sohyun Park^b, Jongheon Jung^c, Su-Hyun Kim^d, Tae-Sung Kim^b, Young Ju Choi^a, Ho Jin Kim^d, Hyeon-Seok Eom^c,*, Jae-Won Hyun^d,*

^aDivision of Infectious Disease, Department of Internal Medicine, Research Institute and Hospital of National Cancer Center, Goyang 10408, South Korea
^bDepartment of Nuclear Medicine, Research Institute and Hospital of National Cancer Center, Goyang 10408, South Korea
^cDepartment of Hemato-oncology, Research Institute and Hospital of National Cancer Center, Goyang 10408, South Korea
^dCenter for Hematologic Malignancy, and Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang 10408, South Korea

JYC and SP contributed equally as first authors.

^*To whom correspondence should be addressed.

Guillain-Barré syndrome after vaccination against COVID-19 has been reported worldwide. Albeit rare, Guillain-Barré syndrome after vaccination is of great public concern given that it could potentially result in life-threatening paralysis. We report the findings of two patients with Guillain-Barré syndrome after receiving the BNT162b2 vaccine (tozinameran, Pfizer–BioNTech) who were in complete remission from diffuse large B-cell lymphoma.